Mersana Therapeutics, Inc.
MRSN
$0.3659
$0.00982.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.75M | 16.36M | 12.60M | 2.29M | 9.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.75M | 16.36M | 12.60M | 2.29M | 9.25M |
| Cost of Revenue | 18.34M | 22.29M | 14.80M | 17.25M | 18.69M |
| Gross Profit | -15.59M | -5.93M | -2.21M | -14.95M | -9.44M |
| SG&A Expenses | 8.93M | 8.89M | 9.86M | 10.50M | 11.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.27M | 31.17M | 24.67M | 27.75M | 30.25M |
| Operating Income | -24.51M | -14.81M | -12.07M | -25.46M | -21.00M |
| Income Before Tax | -24.12M | -14.12M | -11.08M | -24.27M | -19.31M |
| Income Tax Expenses | -- | 0.00 | 418.00K | -- | -- |
| Earnings from Continuing Operations | -24.12M | -14.12M | -11.50M | -24.27M | -19.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.12M | -14.12M | -11.50M | -24.27M | -19.31M |
| EBIT | -24.51M | -14.81M | -12.07M | -25.46M | -21.00M |
| EBITDA | -24.20M | -14.41M | -11.67M | -25.05M | -20.58M |
| EPS Basic | -0.19 | -0.11 | -0.09 | -0.20 | -0.16 |
| Normalized Basic EPS | -0.12 | -0.07 | -0.06 | -0.12 | -0.10 |
| EPS Diluted | -0.19 | -0.11 | -0.09 | -0.20 | -0.16 |
| Normalized Diluted EPS | -0.12 | -0.07 | -0.06 | -0.12 | -0.10 |
| Average Basic Shares Outstanding | 124.47M | 123.56M | 122.72M | 122.44M | 121.43M |
| Average Diluted Shares Outstanding | 124.47M | 123.56M | 122.72M | 122.44M | 121.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |